Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Trial Profile

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2019

At a glance

  • Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms ARTEMIS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jan 2019 Results assessing the co-payments impact on P2Y12 inhibitor use and major cardiovascular events published in the JAMA: the Journal of the American Medical Association
    • 14 Nov 2018 Results assessing the "Halo Effect" of a P2Y12 Inhibitor Copayment Reduction Intervention on Persistence and Adherence With Other Secondary Prevention Medications, presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top